Intercept Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Intercept Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date Intercept Pharmaceuticals Inc Strategy Report
- Understand Intercept Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Intercept Pharmaceuticals Inc (Intercept), a subsidiary of Alfasigma SpA, is a clinical-stage specialty pharmaceutical company with a focus on chronic liver diseases. Its focused research and development (R&D) activities, marketed product: Ocaliva are its major strengths, even as private ownership is a cause for concern. Product pipeline and orphan drug designation could provide growth opportunities for the company. However, competitive pressure, dependence on third-party manufacturers and compliance with regulatory requirements could hamper the company's results of operations.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer